Subscribe to Search results

A meeting was held to discuss ex gratia payments to patients who were infected with Hepatitis C as a result of NHS treatment with blood or blood products. It was attended by Andrew MacLeod and Bob Stock from the Scottish Executive, and Richard Gutowski and David Reay from the Department of Health.

Published on:

A teleconference was arranged by the Department of Health to discuss the inconsistency in the reviewing of natural clearers by clinicians. Professor Christine Lee spoke about her concerns. Clear instructions were needed to eliminate the disparity.

Published on:

A letter from Karin Pappenheim, chief executive of the Haemophilia Society, to Richard Gutowski, Head of Blood Policy Division, expressed concerns regarding the Hepatitis ex gratia scheme.

Published on:

A letter from Professor Christine Lee to William Connon of the Blood Policy Group stated that 15-20% of individuals who were infected with Hepatitis C cleared the virus naturally.

Published on:

An email exchange took place between Peter Stevens, Richard Gutowski and others regarding the approach to be taken to applicants to the Skipton Fund who had cleared the Hepatitis C virus spontaneously.

Published on:

An email exchange took place between Richard Gutowski, Peter Stevens and others regarding the position of spontaneous clearers. Richard Gutowski stated "As far as spontaneous clearers are concerned...our position remains unchanged. They do not come within the scope of the Scheme."

Published on:

The Scottish Expert Group on Financial and Other Support was set up to look at the pros and cons of a system of financial and other support for those harmed by health service treatment where the NHS was not at fault.

Published on:

A disagreement began between the UK Government and Scottish Executive as to whether making payments to relieve financial hardship out of health care treatment was something that the Scottish Executive had a right to legislate on. Malcolm Chisholm said that the advice he had was that this was a devolved matter but he was not sure this was right.

Published on:

The Secretary of State wrote to Malcolm Chisholm informing him that an ex gratia payment scheme for people in Scotland who had been infected with Hepatitis C as a result of treatment with NHS blood/blood products would be accepted as falling within devolved competence.

Published on:

Further nominees for expert groups put forward

Published on:

"The surveillance of transfusion-associated viral hepatitis" was published in the Journal of the American Medical Association. The article supported Dr Allen's striking "ten times" finding.

Published on:

In his book "The Gift Relationship", Professor Richard Titmuss commented on the additional risk created by paid donations mixed in commercial pools in the US.

Published on:

Dr Craske linked the risks of commercial concentrates from large pools with domestic production.

Published on:

A letter from Dr Garrott Allen to Dr Maycock emphasised the risks associated with commercial blood in a mixed combination to bring up an astounding attack rate from one that was relatively unnoticed.

Published on:

Dr Maycock knew the risks associated with commercial blood in a mixed combination to bring up an astounding attack rate; possibly Dr Owen knew of this too.

Published on:

In a Blood Money interview, Dr Craske explained the risk of larger pools, acknowledging that one donor could affect a pool and that Factor 8 should only be used in emergencies and by qualified staff.

Published on:

Dr Owen acknowledged that it was likely that he would have read Craske's article, acknowledging the risks of commercial concentrates from large pools with domestic production.

Published on:

Professor Manucci pointed out that strict adherence to the "small pool concept" in Sweden had given rise to "a very low incidence" of post-transfusion hepatitis in people with Haemophilia B, and suggested that the adoption of such a concept would be "a significant step forward".

Published on:

The Council of Europe recommended that blood collection agencies and pharmaceutical companies should give treating physicians and consumers detailed information about blood and blood related products, including the nature of the donor pool from which the products were derived.

Published on:

Dr James Smith at PFL asked Dr Lane, as the director of BPL, to agree to his increasing the pool size used to 900kg-1,000kg of plasma (roughly 4,500-5,000 donations).

Published on: